市場調查報告書

Luxturna(voretigene neparvovec-rzyl):醫藥品分析與到2030年為止的市場預測

Luxturna (voretigene neparvovec-rzyl) - Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 926204
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Luxturna(voretigene neparvovec-rzyl):醫藥品分析與到2030年為止的市場預測 Luxturna (voretigene neparvovec-rzyl) - Drug Insight and Market Forecast - 2030
出版日期: 2020年02月01日內容資訊: 英文
簡介

本報告提供主要7個國家 (美國,英國,德國,法國,義大利,西班牙,日本)的Luxturna(voretigene neparvovec-rzyl)市場調查,彙整藥品概要,開發趨勢,專利資訊,銷售情況與預測,臨床試驗趨勢,競爭情形等相關資訊。

第1章 產品概要

  • 適應症
  • 作用機制
  • 用法·用量
  • 合成途徑
  • 藥理學
  • 副作用
  • 產品的概述
  • Luxturna(voretigene neparvovec-rzyl)的開發里程碑
  • 上市詳細內容
    • 美國
    • 歐洲
    • 日本
  • 專利詳細內容

第2章 SWOT分析

  • 分析師的觀點

第3章 法規的里程碑

  • 核准
  • 研究開發
  • 臨床試驗資訊
  • 安全性和有效性
  • 產品開發活動

第4章 市場評估

  • 主要7個國家市場分析
  • 美國
  • 歐洲(英國·德國·法國·義大利·西班牙)
  • 日本
  • 主要調查結果

第5章 競爭情形

第6章 新治療方法

第7章 附錄

目錄
Product Code: DIDM0013

Overview

"Luxturna (voretigene neparvovec-rzyl) - Drug Insight and Market Forecast - 2030" report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Luxturna (voretigene neparvovec-rzyl) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details covers mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Luxturna (voretigene neparvovec-rzyl).
  • The report contains historical and forecasted sales for Luxturna (voretigene neparvovec-rzyl) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Luxturna (voretigene neparvovec-rzyl).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Luxturna (voretigene neparvovec-rzyl) Analytical Perspective by DelveInsight

  • In-depth Luxturna (voretigene neparvovec-rzyl) Market Assessment

This report provides a detailed market assessment of Luxturna (voretigene neparvovec-rzyl) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

  • Luxturna (voretigene neparvovec-rzyl) Clinical Assessment

The report provides the clinical trials information of Luxturna (voretigene neparvovec-rzyl) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights

  • In the coming years, the market scenario for Luxturna (voretigene neparvovec-rzyl) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Luxturna (voretigene neparvovec-rzyl) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Luxturna (voretigene neparvovec-rzyl) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Luxturna (voretigene neparvovec-rzyl).
  • Our in-depth analysis of the sales data of Luxturna (voretigene neparvovec-rzyl) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Luxturna (voretigene neparvovec-rzyl) in the market.

Key Questions

  • What is the prescribed dosage and strengths of Luxturna (voretigene neparvovec-rzyl) are available in the market?
  • What are the common adverse reactions or side effects of Luxturna (voretigene neparvovec-rzyl)?
  • What is the product type, route of administration and mechanism of action of Luxturna (voretigene neparvovec-rzyl)?
  • What are the chemical specifications of Luxturna (voretigene neparvovec-rzyl)?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Luxturna (voretigene neparvovec-rzyl), and what is its future?
  • What are the marketed details of Luxturna (voretigene neparvovec-rzyl) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Luxturna (voretigene neparvovec-rzyl) and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Luxturna (voretigene neparvovec-rzyl)?
  • In which countries Luxturna (voretigene neparvovec-rzyl) got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Luxturna (voretigene neparvovec-rzyl)?
  • How the safety and efficacy results determined the approval of Luxturna (voretigene neparvovec-rzyl)?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Luxturna (voretigene neparvovec-rzyl) development?
  • What are the key designations that have been granted to Luxturna (voretigene neparvovec-rzyl)?
  • What is the historical and forecasted market scenario of Luxturna (voretigene neparvovec-rzyl)?
  • How is the market trend of Luxturna (voretigene neparvovec-rzyl) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Luxturna (voretigene neparvovec-rzyl)?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

Table of Contents

1. Product Overview

  • 1.1. Indication
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
    • 1.4.1 Dosage Forms and Strengths
  • 1.4. Route of Synthesis
  • 1.5. Pharmacology
    • 1.4.2 Pharmacodynamics
    • 1.4.3 Pharmacokinetics
  • 1.6. Adverse Reactions
  • 1.7. Product Snapshot
  • 1.8. Development Milestones of Luxturna (voretigene neparvovec-rzyl)
  • 1.9. Marketed Details
    • 1.4.4 United States
    • 1.4.5 Europe
    • 1.4.6 Japan
  • 1.10. Patent Details

2. SWOT Analysis

  • 2.1. Analyst Views

3. Regulatory Milestones

  • 3.1. Approvals
  • 3.2. Research and Development
  • 3.3. Clinical Trials Information
  • 3.4. Safety and Efficacy
  • 3.5. Product Developmental Activities

4. Market Assessment

  • 4.1. 7MM Market Analysis
  • 4.2. United States
  • 4.3. Europe
  • 4.4. Japan
  • 4.5. Key Findings

5. Market Competitors

6. Emerging Therapies

7. Appendix

  • 7.1. Report Purchase Options

List of Tables

  • Table 1 Luxturna (voretigene neparvovec-rzyl), Description
  • Table 2 Luxturna (voretigene neparvovec-rzyl), Trial Diversification
  • Table 3 Luxturna (voretigene neparvovec-rzyl), Marketed Details United States
  • Table 4 Luxturna (voretigene neparvovec-rzyl), Marketed Details Europe
  • Table 5 Luxturna (voretigene neparvovec-rzyl), Marketed Details Japan
  • Table 6 Patent Details: Luxturna (voretigene neparvovec-rzyl)
  • Table 7 Luxturna (voretigene neparvovec-rzyl), Clinical Trial Description, 2020
  • Table 8 Safety and Efficacy Results for Luxturna (voretigene neparvovec-rzyl)
  • Table 9 Luxturna (voretigene neparvovec-rzyl), 7MM Market Size from 2017 to 2030 (in Million USD)
  • Table 10 Luxturna (voretigene neparvovec-rzyl), US Market Size from 2017 to 2030 (in Million USD)
  • Table 11 Luxturna (voretigene neparvovec-rzyl), EU Market Size from 2017 to 2030 (in Million USD)
  • Table 12 Luxturna (voretigene neparvovec-rzyl), EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Table 13 Luxturna (voretigene neparvovec-rzyl), Japan Market Size from 2017 to 2030 (in Million USD)
  • Table 14 Market Competitors
  • Table 15 Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of Luxturna (voretigene neparvovec-rzyl)
  • Figure 2 Patent Details, Luxturna (voretigene neparvovec-rzyl)
  • Figure 3 Luxturna (voretigene neparvovec-rzyl), 7MM Market Size from 2017 to 2030 (in Million USD)
  • Figure 4 Luxturna (voretigene neparvovec-rzyl), US Market Size from 2017 to 2030 (in Millions USD)
  • Figure 5 Luxturna (voretigene neparvovec-rzyl), EU Market Size from 2017 to 2030 (in Millions USD)
  • Figure 6 Luxturna (voretigene neparvovec-rzyl), EU5 Market Size from 2017 to 2030 (in Millions USD)
  • Figure 7 Luxturna (voretigene neparvovec-rzyl), Japan Market Size from 2017 to 2030 (in Millions USD)